The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 2008, 180, 2376 -2384
Copyright © 2008 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Castilow, E. M.
Right arrow Articles by Varga, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Castilow, E. M.
Right arrow Articles by Varga, S. M.

IL-13 Is Required for Eosinophil Entry into the Lung during Respiratory Syncytial Virus Vaccine-Enhanced Disease1

Elaine M. Castilow*, David K. Meyerholz{dagger} and Steven M. Varga2,*,{ddagger}

* Interdisciplinary Graduate Program in Immunology, {dagger} Department of Pathology, and {ddagger} Department of Microbiology, University of Iowa, Iowa City, IA 52242

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract disease in children. Children previously vaccinated with a formalin-inactivated RSV vaccine experienced enhanced morbidity and mortality upon natural RSV infection. Histological analysis revealed the presence of eosinophils in the pulmonary infiltrate of the vaccinated children. Eosinophils are characteristic of Th2 responses, and Th2 cells are known to be necessary to induce pulmonary eosinophilia in RSV-infected BALB/c mice previously immunized with a recombinant vaccinia virus (vv) expressing the RSV G protein (vvG). Using IL-13-deficient mice, we find that IL-13 is necessary for eosinophils to reach the lung parenchyma and airways of vvG-immunized mice undergoing RSV challenge infection. IL-13 acts specifically on eosinophils as the magnitude of pulmonary inflammation, RSV G protein-specific CD4 T cell responses, and virus clearance were not altered in IL-13-deficient mice. After RSV challenge, eosinophils were readily detectable in the blood and bone marrow of vvG-immunized IL-13-deficient mice, suggesting that IL-13 is required for eosinophils to transit from the blood into the lung. Pulmonary levels of CCL11 and CCL22 protein were significantly reduced in IL-13-deficient mice indicating that IL-13 mediates the recruitment of eosinophils into the lungs by inducing the production of chemokines important in Th2 cell and eosinophil chemotaxis.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by funding from the American Heart Association Predoctoral Fellowship (to E.M.C.), University of Iowa Department of Pathology (to D.K.M.), and National Institutes of Health Grant AI 063520 (to S.M.V.).

2 Address correspondence and reprint requests to Dr. Steven M. Varga, Department of Microbiology, University of Iowa, 51 Newton Road, Iowa City, IA 52242. E-mail address: steven-varga{at}uiowa.edu

3 Abbreviations used in this paper: RSV, respiratory syncytial virus; FI-RSV, formalin-inactivated RSV; vv, vaccinia virus; β-gal, β-galactosidase; BAL, bronchoalveolar lavage; MBP, major basic protein; N, nucleocapsid protein.




This article has been cited by other articles:


Home page
J. Gen. Virol.Home page
J. Kovacs-Nolan, J. W. Mapletoft, Z. Lawman, L. A. Babiuk, and S. van Drunen Littel-van den Hurk
Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice
J. Gen. Virol., August 1, 2009; 90(8): 1892 - 1905.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. M. Percopo, Z. Qiu, S. Phipps, P. S. Foster, J. B. Domachowske, and H. F. Rosenberg
Pulmonary Eosinophils and Their Role in Immunopathologic Responses to Formalin-Inactivated Pneumonia Virus of Mice
J. Immunol., July 1, 2009; 183(1): 604 - 612.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. R. Olson and S. M. Varga
Fas Ligand Is Required for the Development of Respiratory Syncytial Virus Vaccine-Enhanced Disease
J. Immunol., March 1, 2009; 182(5): 3024 - 3031.
[Abstract] [Full Text] [PDF]


Home page
Vet PatholHome page
D. K. Meyerholz, J. Rodgers, E. M. Castilow, and S. M. Varga
Alcian Blue and Pyronine Y Histochemical Stains Permit Assessment of Multiple Parameters in Pulmonary Disease Models
Vet. Pathol., March 1, 2009; 46(2): 325 - 328.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
D. K. Meyerholz, M. A. Griffin, E. M. Castilow, and S. M. Varga
Comparison of Histochemical Methods for Murine Eosinophil Detection in an RSV Vaccine-enhanced Inflammation Model
Toxicol Pathol, February 1, 2009; 37(2): 249 - 255.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. R. Olson, S. M. Hartwig, and S. M. Varga
The Number of Respiratory Syncytial Virus (RSV)-Specific Memory CD8 T Cells in the Lung Is Critical for Their Ability to Inhibit RSV Vaccine-Enhanced Pulmonary Eosinophilia
J. Immunol., December 1, 2008; 181(11): 7958 - 7968.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. M. Castilow, K. L. Legge, and S. M. Varga
Cutting Edge: Eosinophils Do Not Contribute to Respiratory Syncytial Virus Vaccine-Enhanced Disease
J. Immunol., November 15, 2008; 181(10): 6692 - 6696.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2008 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2008 by The American Association of Immunologists, Inc. All rights reserved.